

IMPORTANT INFORMATION | FOR PATIENTS

Contact your doctor **IMMEDIATELY** or seek emergency care if you have **any of these symptoms:**

Symptoms of Cytokine Release Syndrome (CRS)

- Fever (38°C or higher)
- Low blood pressure
- Shortness of breath, confusion, restlessness, trouble breathing
- Fast or irregular heartbeat: palpitations, dizziness
- Headache
- Chills
- Nausea
- Vomiting

Symptoms of Neurologic problems

- Trouble speaking, memory loss, personality changes (encephalopathy)
- Confusion
- Feeling disorientated or having difficulty thinking clearly (delirium)
- Seizure
- Loss of balance or coordination (ataxia)
- Weakness or numbness of arms and legs
- Shakiness of your hands or limbs (tremor)
- Headache

These are not all of the possible side effects you may have when taking IMDELLTRA. If you experience any side effects not listed here, tell your healthcare provider.



Tell your healthcare provider about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

This material was developed by Amgen as part of the risk minimisation plan for IMDELLTRA and is not intended for promotional use.

2 ND INFUSION (DAY 8)
1 ST INFUSION (DAY 1)
DATE AND TIME OF IMDELLTRA INFUSION:
HOSPITAL/CLINIC NAME:
AFTER HOURS PHONE:
OFFICE PHONE:
DOCTOR NAME:
PATIENT NAME:

- This patient has received an immunotherapy Bispecific T-cell Engager (BiTE®) molecule called IMDELLTRA (tarlatamab).
- IMDELLTRA is indicated for small cell lung cancer.
- IMDELLTRA may cause side effects which may be severe and life-threatening such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
- For further information on IMDELLTRA and the management of CRS and ICANS with IMDELLTRA, please consult the IMDELLTRA Singapore Package Insert.

FOR
HEALTHCARE
PROVIDERS

IMPORTANT INFORMATION & CONTACT

IMDELLTRA (TARLATAMAB) PATIENT ALERT CARD

KEEP this card with you at all times.
SHOW THIS CARD to any healthcare providers
involved in your care.



CONTACT your doctor if you experience any of the symptoms present in this card.

SEEK emergency care if your doctor is not available.



IMPORTANT TO REMEMBER

Your healthcare provider will monitor you for 22 to 24 hours from the start of the IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8 in an appropriate healthcare setting. Additionally, you should remain within 1-hour of an appropriate healthcare setting for a total of 48 hours after the start of the IMDELLTRA infusion on Cycle 1 Day 1 and Cycle 1 Day 8, accompanied by a caregiver.